Company Encyclopedia
View More
name
PHARMARON
03759.HK
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services.
676.35 B
03759.HKMarket value -Rank by Market Cap -/-

Financial Score

31/12/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking5/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.80%B
    • Profit Margin11.17%B
    • Gross Margin34.69%C
  • Growth ScoreB
    • Revenue YoY13.65%B
    • Net Profit YoY-20.54%D
    • Total Assets YoY7.96%B
    • Net Assets YoY6.75%B
  • Cash ScoreB
    • Cash Flow Margin895.50%B
    • OCF YoY13.65%B
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreC
    • Gearing Ratio41.16%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | Is Pharmaron's low expected with reduced volume consolidation? News-driven factors may become a turning point

    Pharmaron (3759.HK) has recently shown a lackluster performance, remaining in a state of continuous volume contraction and consolidation. The daily MACD still maintains a death cross, with the green histogram showing no significant convergence, indicating a strong bearish atmosphere. The current stock price is fluctuating within a narrow range at a key support level, and multiple retests have not seen strong buying interest, reflecting limited willingness to support at low levels, while the main funds are in a wait-and-see state. On the fundamental side, although Pharmaron is one of the leading companies in the CXO field, the overall market for health and new drug development has shown significant differentiation, with noticeable adjustments in institutional holdings. The company currently lacks sufficient impressive performance catalysts in the short term, compounded by the pressure of industry sector adjustments, limiting short-term rebound momentum. From a technical perspective, if the trading volume does not show a recovery trend in the short term, the possibility of exploring new lows cannot be ruled out. If the previous low is effectively broken, attention should be paid to the strength of fund defense in the next support range, as the technical pattern indicates more apparent downward risks in the short to medium term. Operational advice: prioritize defense and maintain a wait-and-see approach. If there are subsequent industry benefits or significant improvements in performance, it may bring short-term rebound opportunities, but currently, neither technical nor funding aspects have shown bottom signals, so caution is advised, and it is better to wait for volume-price coordination before considering entry

    Technical Forecast·
    Technical Forecast·
    Posts
    View More

    $XTALPI(02228.HK)

    Short selling data this morning: 02228 Pharmaron (Beijing) Co., Ltd.-P 705,000 5,143,150. Average selling price 7.29

    I expect the closing price to be above this level.

    $XTALPI(02228.HK)

    Today's trend is "not good-looking". Let's look at the data, short selling:

      2228  Pharmaron-P         277,000      2,131,420

     

    This small proportion of volume is not the reason why t...

    $XTALPI(02228.HK)We should still keep playing Pharmaron recently. The US stocks are also freaking hot as hell. 😜

    $XTALPI(02228.HK) Short interest data this morning: 2228 Pharmaron (Beijing) Co., Ltd.-P         475,000      3,516,420

     

    Average price: HK$7.4. This idiot has already lost HK$0.6 now.....